

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 November 2022 (24.11.2022)



(10) International Publication Number
WO 2022/245991 A1

(51) International Patent Classification:

A61K 31/166 (2006.01) C07C 317/38 (2006.01)
A61K 31/40 (2006.01) A61K 31/00 (2006.01)
A61P 25/18 (2006.01) A61P 25/00 (2006.01)
A61P 25/28 (2006.01)

(21) International Application Number:

PCT/US2022/029900

(22) International Filing Date:

18 May 2022 (18.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/189,905 18 May 2021 (18.05.2021) US

(71) Applicant: **LB PHARMACEUTICALS INC.** [US/US];
575 Madison Avenue, Floor 10, New York, New York
10022 (US).

(72) Inventors: **VAINO, Andrew R.**; New York, New
York (US). **GRATTAN, Vincent T.**; New York (US).
PRENSKY, Zachary; New York, New York (US).

(74) Agent: **WANG, Yingli** et al.; Perkins Coie LLP, P.O. Box
1247, Seattle, Washington 98111-1247 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,

(54) Title: PSYCHOTROPIC AGENTS AND USES THEREOF

Dopamine %RO, 50 mg LB-102 (n = 4)




Fig. 1A

(57) **Abstract:** Disclosed herein are novel uses of amisulpride derivatives and pharmaceutical compositions thereof, alone or in combination with other CNS active agents to antagonize dopamine and/or serotonin (e.g., 5-HT_{2a}, 5-HT₇) and/or alpha 2 receptors in a subject. Amisulpride derivatives or pharmaceutical compositions thereof disclosed herein may be used, alone or in combination with other CNS active agents, for the treatment of one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT_{2a}, 5-HT₇) and/or alpha 2 receptors in a subject. Amisulpride derivatives or pharmaceutical compositions thereof disclosed herein may be used alone or in combination with other CNS active agents for the treatment of one or more disorders associated with abnormal levels of dopamine and/or serotonin in the brain.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*